Ingredion Inc
Ingredion (INGR) reported Q2 2026 net sales of $1.85 billion (+1%) and adjusted operating income of $258 million (-5%). Adjusted EPS was $2.82. Results reflected volume growth in Texture & Healthful Solutions, but currency headwinds in Mexico and Argo facility issues. Full-year 2026 adjusted EPS guidance is $10.30 to $10.90; cash from ops $700m to $800m. Tate & Lyle acquisition pending.
Ingredion (INGR) reported Q2 2026 results and reaffirmed its full-year outlook. For Q3 2026, it expects net sales up low single digits. Full-year 2026 sales are projected flat to up low single digits, with reported EPS of $9.15 to $9.75. It expects 2026 operating income down low double digits. A DCF fair value is cited at $88.23 versus a $104.33 close.
Brazil’s competition authority cleared Ingredion’s proposed $3.6 billion acquisition of Tate & Lyle under a fast-track review. The deal was notified July 20 and approved after the agency’s assessment. The clearance removes a regulatory hurdle for the transaction, which could affect both companies’ deal-related outlook.
Over the past 7 days, alphai's AI scored 4 news stories mentioning INGR (Ingredion Inc). Coverage has skewed bullish: 2 bullish, 2 neutral, and 0 bearish.
Recent INGR coverage spans earnings, mergers & acquisitions and insider activity.
In the last 30 days, INGR insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($170K). The most active reporter was Fischer David B with 1 filing.
Near-term trading focus is on margin pressure from Argo operational issues and tapioca cost inflation, offset by specialty segment strength and deal-related synergy targets.
Reaffirmed FY outlook with mixed margin signals likely keeps valuation debate centered on whether volume and FX can offset price-mix pressure and Pakistan stake sale effects.
Regulatory clearance in Brazil lowers probability of deal delay or blockage, supporting deal completion odds.
A routine insider open-market sale under a Form 4, with no 10b5-1 plan stated, may modestly affect near-term sentiment but is unlikely to change fundamentals.
The acquisition is a growth and margin-expansion catalyst for Ingredion, but execution and integration risk can cap upside.
alphai scores every news story that mentions INGR with an AI model for sentiment and relevance, and aggregates insider trades from Ingredion Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Ingredion (INGR) reported Q2 2026 net sales of $1.85 billion (+1%) and adjusted operating income of $258 million (-5%). Adjusted EPS was $2.82. Results reflected volume growth in Texture & Healthful Solutions, but currency headwinds in Mexico and Argo facility issues. Full-year 2026 adjusted EPS guidance is $10.30 to $10.90; cash from ops $700m to $800m. Tate & Lyle acquisition pending.
7 min readIngredion (INGR) reported Q2 2026 results and reaffirmed its full-year outlook. For Q3 2026, it expects net sales up low single digits. Full-year 2026 sales are projected flat to up low single digits, with reported EPS of $9.15 to $9.75. It expects 2026 operating income down low double digits. A DCF fair value is cited at $88.23 versus a $104.33 close.
6 min readBrazil’s competition authority cleared Ingredion’s proposed $3.6 billion acquisition of Tate & Lyle under a fast-track review. The deal was notified July 20 and approved after the agency’s assessment. The clearance removes a regulatory hurdle for the transaction, which could affect both companies’ deal-related outlook.
1 min readFischer David B sold 1,662 shares of Ingredion Inc (INGR) at $102.31 ($0.17M total) on 2026-08-05.
2 min readAccording to the companies, Tate & Lyle will be acquired by US ingredients maker Ingredion in a £2.7 billion deal. Ingredion will pay up to 615p per Tate & Lyle share, including 595p cash plus dividend payments. The offer values Tate at £2.7 billion, or £3.7 billion including debt, and represents a 64% premium. Ingredion must act by June 11.
4 min readIngredion (INGR) reported Q2 2026 adjusted EPS of $2.82, above the $2.73 Zacks estimate, with net sales up 0.9% to $1.85B. Texture & Healthful Solutions volumes rose 7%. Gross profit and operating income declined due to Argo manufacturing issues, higher input costs, and Mexico FX/macro headwinds. 2026 guidance was reaffirmed.
4 min readIngredion (NYSE: INGR) reported Q2 CY2026 revenue of $1.85B, flat year on year and slightly above analysts’ $1.83B estimate. Non-GAAP EPS was $2.82, 3.6% above consensus. Management lowered full-year adjusted EPS guidance midpoint to $10.60. Operating margin fell to 10.2% from 14.8% a year earlier, citing Argo facility issues and input-cost pressures, while Texture & Healthful Solutions volume grew for nine straight quarters.
6 min readIngredion’s Q2 2026 earnings call said Texture & Healthful Solutions posted ninth straight quarter of volume growth, while the Argo facility returned to normal rates by late June after mechanical and thermal issues. Management reaffirmed 2026 adjusted EPS of $10.30 to $10.90, citing Mexico currency and macro headwinds, tapioca cost pass-through lag, and planned Tate & Lyle acquisition.
7 min readIngredion (NYSE:INGR) reported Q2 2026 adjusted EPS of $2.82 on revenue of $1.85B, slightly above estimates. Net sales rose 1% but adjusted operating income fell 5% to $258M as gross margin dropped 300 bps to 23.0%. The company cited margin pressure from higher input costs and Argo facility issues, while Texture & Healthful Solutions volume grew 7%.
6 min readIngredion Inc. will acquire Tate & Lyle PLC for about £2.7 billion, or $3.6 billion, to expand capabilities in texturants, sugar reduction and fortification, according to Ingredion. The deal, announced May 14, would create a combined business with sales near $10 billion. Tate & Lyle FY ended March 31 sales were £2.0 billion, down 3%.
4 min read
